Cyclic AMP response to recombinant human relaxin by cultured human endometrial cells—A specific and high throughput in vitro bioassay
References (22)
- et al.
Biochem. Biophys. Res. Commun.
(1987) - et al.
Ann. N. Y. Acad. Sci.
(1959) - et al.
Endocrinology
(1976) - et al.
Endocrinology
(1957) - et al.
Endocrinology
(1989) - et al.
- et al.
- et al.
J. Endocrinol.
(1989) - et al.
J. Clin. Endocrinol. Metab.
(1990) - et al.
Endocrinology
(1982)
Cited by (82)
Understanding relaxin signalling at the cellular level
2019, Molecular and Cellular EndocrinologyCitation Excerpt :cAMP signals by activating protein kinase A (PKA), Epac, and cyclic nucleotide-gated ion channels. Relaxin administration acutely increases cAMP activity across a range of cell types, including normal human endometrial (NHE) cells (Fei et al., 1990), endometrial stromal cells (Bartsch et al., 2004), human myometrial cells (Heng et al., 2008), human decidual cells from fetal membranes (Kern and Bryant-Greenwood, 2009), and human decidual macrophages (Horton et al., 2011). Relaxin also increases cAMP activity in rat anterior pituitary cells (Cronin et al., 1987) and various human cancer cell types including MCF-7 breast cancer cells (Bigazzi et al., 1992), monocytic leukaemia THP-1 cells (Parsell et al., 1996), prostate cancer cells (Silvertown et al., 2007; Vinall et al., 2011), and some glioblastoma cells (Glogowska et al., 2013).
Membrane receptors: Structure and function of the relaxin family peptide receptors
2010, Molecular and Cellular EndocrinologyRelaxin receptor-LGR7 (RXFP1)
2008, xPharm: The Comprehensive Pharmacology ReferenceA novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation
2007, Regulatory PeptidesRelaxin signalling in THP-1 cells uses a novel phosphotyrosine-dependent pathway
2007, Molecular and Cellular Endocrinology'Relaxin' the stiffened heart and arteries: The therapeutic potential for relaxin in the treatment of cardiovascular disease
2006, Pharmacology and Therapeutics